Lombard on verge of pivotal trial for Aorfix
This article was originally published in Clinica
Executive Summary
Lombard Medical Technologies is on the verge of beginning US pivotal trials for its Aorfix stent graft for treating abdominal aortic aneurysms (AAAs), after it received conditional approval from the US FDA of its supplemental investigational device exemption (IDE) application.